| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T4 |
0-102 |
Sentence |
denotes |
The basic characteristics between survivors and non-survivors with COVID-19 were presented in Table 1. |
| T5 |
103-272 |
Sentence |
denotes |
Among a total of 44,672 patients with laboratory confirmation of SARS-CoV-2 infection, 1023 (2.3%) patients were dead as of February 11, 2020, the last day of follow-up. |
| T6 |
273-387 |
Sentence |
denotes |
The fatality rate was increasing with ages and even up to 14.8% in patients aged above 80 years old (see Fig. 1a). |
| T7 |
388-535 |
Sentence |
denotes |
The prevalence of COVID-19 between men and women was pretty close (51.4% vs. 48.6%), which is different from previous report (58.1% vs. 41.9%) [3]. |
| T8 |
536-690 |
Sentence |
denotes |
Notably, the fatality rate of male patients was significantly higher than that of female patients (RR = 1.67, 95%CI = 1.47–1.89, p < 0.001) (see Fig. 1b). |
| T9 |
691-1057 |
Sentence |
denotes |
Furthermore, cardiovascular disease (RR = 6.75, 95%CI = 5.40–8.43, p < 0.001), hypertension (HR = 4.48, 95%CI = 3.69–5.45, p < 0.001), diabetes (RR = 4.43, 95%CI = 3.49–5.61, p < 0.001), respiratory disease (RR = 3.43, 95%CI = 2.42–4.87, p < 0.001), and cancers (RR = 2.926, 95%CI = 1.34–6.41, p = 0.006) were the risk factors for fatality of patients with COVID-19. |
| T10 |
1058-1131 |
Sentence |
denotes |
Table 1 Characteristics between survivors and non-survivors with COVID-19 |
| T11 |
1132-1240 |
Sentence |
denotes |
Characteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p |
| T12 |
1241-1251 |
Sentence |
denotes |
Age, n (%) |
| T13 |
1252-1281 |
Sentence |
denotes |
0– 416 (0.9%) 0 416 (0.9%) 0 |
| T14 |
1282-1321 |
Sentence |
denotes |
10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2 |
| T15 |
1322-1363 |
Sentence |
denotes |
20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2 |
| T16 |
1364-1408 |
Sentence |
denotes |
30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2 |
| T17 |
1409-1453 |
Sentence |
denotes |
40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4 |
| T18 |
1454-1502 |
Sentence |
denotes |
50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3 |
| T19 |
1503-1549 |
Sentence |
denotes |
60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6 |
| T20 |
1550-1594 |
Sentence |
denotes |
70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0 |
| T21 |
1595-1641 |
Sentence |
denotes |
≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8 |
| T22 |
1642-1658 |
Sentence |
denotes |
Severity*, n (%) |
| T23 |
1659-1707 |
Sentence |
denotes |
Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0 |
| T24 |
1708-1745 |
Sentence |
denotes |
Severe 6168 (13.8%) 0 6168 (14.1%) 0 |
| T25 |
1746-1796 |
Sentence |
denotes |
Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0 |
| T26 |
1797-1810 |
Sentence |
denotes |
Gender, n (%) |
| T27 |
1811-1887 |
Sentence |
denotes |
Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) < 0.001 |
| T28 |
1888-1941 |
Sentence |
denotes |
Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7 |
| T29 |
1942-1961 |
Sentence |
denotes |
Comorbidity#, n (%) |
| T30 |
1962-2042 |
Sentence |
denotes |
Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) < 0.001 |
| T31 |
2043-2116 |
Sentence |
denotes |
Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) < 0.001 |
| T32 |
2117-2203 |
Sentence |
denotes |
Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) < 0.001 |
| T33 |
2204-2285 |
Sentence |
denotes |
Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) < 0.001 |
| T34 |
2286-2351 |
Sentence |
denotes |
Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006 |
| T35 |
2352-2394 |
Sentence |
denotes |
*Missing data (n = 257 in survivors group) |
| T36 |
2395-2480 |
Sentence |
denotes |
#Missing data (n = 617 in the non-survivors group, n = 23,073 in the survivors group) |
| T37 |
2481-2554 |
Sentence |
denotes |
Fig. 1 Fatality rate distribution of age (a) and gender (b). ***p < 0.001 |
